227 filings
Page 5 of 12
8-K
mdv 3wk5ubqm21cf
1 Aug 17
Rigel Announces Second Quarter 2017 Financial Results and Provides Company Update
12:00am
8-K
rd1935o4n6
30 May 17
Entry into a Material Definitive Agreement
12:00am
8-K
8f6osz0
12 May 17
Rigel Announces First Quarter 2017 Financial Results and Provides Company Update
12:00am
8-K
7e8hto
7 Mar 17
Rigel Announces Fourth Quarter 2016 and Year End 2016 Financial Results and Provides Company Update
12:00am
8-K
z338p kql1s
24 Feb 17
Departure of Directors or Certain Officers
12:00am
8-K
kuezybsxt26un3ohxux
8 Feb 17
Departure of Directors or Certain Officers
12:00am
8-K
d6fazk8c6kbf38u
31 Jan 17
Other Events
12:00am
8-K
zeu3927
30 Jan 17
Results of Operations and Financial Condition
12:00am
8-K
k4xg0s03 dbsv
1 Nov 16
Rigel Announces Third Quarter 2016 Financial Results and Provides Company Update
12:00am
8-K
l6i0qrrj2l qa90hx
20 Oct 16
Rigel Announces Results from the Second FIT Phase 3 Study and the Long-Term Open-Label Extension Study for Fostamatinib in ITP
12:00am
8-K
7q668ok
11 Oct 16
Departure of Directors or Certain Officers
12:00am
8-K
emzc b04ndbqn
15 Sep 16
Cost Associated with Exit or Disposal Activities
12:00am
8-K
j11za 4w3zw5w
30 Aug 16
Agenda Safe Harbor Statement D. Vance Introduction and Overview R. Rodriguez FIT 1 Phase 3 Results A. Duliege FIT 1 Phase 3 Commentary J. Bussel Q&A
12:00am
8-K
xfexahr4hj2o6uq
2 Aug 16
Rigel Announces Second Quarter 2016 Financial Results and Provides Portfolio Update
12:00am
8-K
b18 dljg3is8ekiit
12 May 16
Submission of Matters to a Vote of Security Holders
12:00am
8-K
lsf24tk6hu
3 May 16
Rigel Announces First Quarter 2016 Financial Results
12:00am
8-K
3en3ud
8 Mar 16
Rigel Announces Fourth Quarter and Year End 2015 Financial Results
12:00am
8-K
hqmrjh6y8r5utbwl
8 Mar 16
Rigel Names Anne-Marie Duliege, M.D., M.S. As Chief Medical Officer
12:00am
8-K
3ijoekarcfv
29 Jan 16
Departure of Directors or Certain Officers
12:00am
8-K
ea1llwfg51j1psay4sj
3 Nov 15
Rigel Announces Third Quarter 2015 Financial Results
12:00am